BriaCell Therapeutics Corp. (TSE:BCT – Free Report) – Investment analysts at HC Wainwright issued their FY2028 EPS estimates for BriaCell Therapeutics in a report released on Tuesday, October 3rd. HC Wainwright analyst E. Bodnar expects that the company will earn ($1.77) per share for the year. HC Wainwright currently has a “Buy” rating on the stock.
BriaCell Therapeutics Stock Down 1.4 %
BCT stock opened at C$7.85 on Wednesday. BriaCell Therapeutics has a 52 week low of C$5.77 and a 52 week high of C$10.81. The company’s fifty day simple moving average is C$8.84. The company has a market capitalization of C$125.44 million, a price-to-earnings ratio of -28.04 and a beta of 1.66.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab.
Featured Articles
- Five stocks we like better than BriaCell Therapeutics
- Where Do I Find 52-Week Highs and Lows?
- Institutions Are Buying Under Appreciated Consumer Staples Now
- What Are Defense Contractor Stocks? How to Invest in Defense
- 3 Stocks For the Resurgent Energy Rally
- What’s a Sound Playbook for Investors During Election Years?
- Zscaler: A Leader in Cybersecurity Soars with Strong Earnings
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
